<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00691002</url>
  </required_header>
  <id_info>
    <org_study_id>LEO 80190-O21</org_study_id>
    <nct_id>NCT00691002</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds</brief_title>
  <official_title>Calcipotriol Plus Hydrocortisone in Psoriasis Vulgaris on the Face and on the Intertriginous Areas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are few therapies suitable for the treatment of psoriasis on the face and skin folds.&#xD;
      As these areas are sensitive, irritation and other adverse reactions are more common than&#xD;
      elsewhere on the body. The purpose of the study is to compare the efficacy and safety of once&#xD;
      daily treatment for up to 8 weeks of an ointment containing calcipotriol 25 mcg/g plus&#xD;
      hydrocortisone 10 mg/g with calcipotriol 25 mcg/g in the ointment vehicle, hydrocortisone 10&#xD;
      mg/g in the ointment vehicle and the ointment vehicle alone in patients with psoriasis&#xD;
      vulgaris on the face and on the intertriginous areas (= double-blind phase). Furthermore, the&#xD;
      safety and efficacy will be evaluated for up to 60 weeks treatment as required of&#xD;
      calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g ointment in psoriasis vulgaris on the face&#xD;
      and intertriginous areas (= open-label phase).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With &quot;Controlled Disease&quot; According to the Investigator's Global Assessment(IGA) of Disease Severity of the Face at Week 8 (Visit 6) in the Double-blind Phase</measure>
    <time_frame>At Week 8 (end of treatment for double-blind phase)</time_frame>
    <description>The (sub) investigator made an assessment of the disease severity of the face using the 6-category scale below.&#xD;
Clear, Almost clear, Mild, Moderate, Severe, Very severe&#xD;
The assessment was made considering the condition of psoriasis vulgaris of the face at the time of the evaluation, not in relation to the condition at a previous visit.&#xD;
For subjects with a baseline (Visit 1) severity of moderate or worse - &quot;controlled disease&quot; of the face was defined as clear or almost clear according to the IGA of disease severity of the face.&#xD;
For subjects with a baseline (Visit 1) severity of mild - &quot;controlled disease&quot; of the face was defined as clear according to the IGA of disease severity of the face.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With &quot;Controlled Disease&quot; According to the IGA of Disease Severity of the Face at Week 4 (Visit 4) in the Double-blind Phase</measure>
    <time_frame>At Week 4</time_frame>
    <description>The assessment of the disease severity of the face was made using the 6-category scale below.&#xD;
Clear Almost clear Mild Moderate Severe Very severe&#xD;
The assessment was made considering the condition of psoriasis vulgaris of the face at the time of the evaluation, not in relation to the condition at a previous visit.&#xD;
For subjects with a baseline severity of moderate or worse - &quot;controlled disease&quot; of the face was defined as clear or almost clear according to the IGA of disease severity of the face.&#xD;
For subjects with a baseline severity of mild - &quot;controlled disease&quot; of the face was defined as clear according to the IGA of disease severity of the face.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With &quot;Success&quot; According to Total Sign Score (TSS) of the Face at Week 8 (Visit 6) in the Double-blind Phase</measure>
    <time_frame>At Week 8 (end of treatment for double-blind phase)</time_frame>
    <description>&quot;Success&quot; was defined as a TSS score of 0 or 1.&#xD;
For each clinical sign, a single score, reflecting the average severity of all psoriatic lesions on the face was determined according to the scale below:&#xD;
Redness 0 = none (no erythema) 1 = mild (faint erythema, pink to very light red) 2 = moderate (definite light red erythema) 3 = severe (dark red erythema) 4 = very severe (very dark red erythema) Thickness 0 = none (no plaque elevation) 1 = mild (slight, barely perceptible elevation) 2 = moderate (definite elevation but not thick) 3 = severe (definite elevation, thick plaque with sharp edge) 4 = very severe (very thick plaque with sharp edge) Scaliness 0 = none (no scaling) 1 = mild (sparse, fine-scale lesions, only partially covered) 2 = moderate (coarser scales, most of lesions covered) 3 = severe (entire lesion covered with coarse scales) 4 = very severe (very thick coarse scales, possibly fissured)&#xD;
The sum of the three scores constituted a TSS ranging from 0 to 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With &quot;Controlled Disease&quot; According to the IGA of Disease Severity of the Intertriginous Areas at Week 8 (Visit 6) in the Double-blind Phase</measure>
    <time_frame>At Week 8 (end of treatment for double-blind phase)</time_frame>
    <description>The (sub)investigator made an assessment of the disease severity of the intertriginous areas using the 6-category scale below.&#xD;
Clear, Almost clear, Mild, Moderate, Severe, Very severe The assessment was made considering the condition of psoriasis vulgaris of the intertrigi-nous areas at the time of the evaluation, not in relation to the condition at a previous visit.&#xD;
For subjects with a baseline severity of moderate or worse - &quot;controlled disease&quot; of the intertriginous areas was defined as clear or almost clear according to the IGA of disease severity of the intertriginous areas.&#xD;
For subjects with a baseline severity of mild - &quot;controlled disease&quot; of the intertriginous areas was defined as clear according to the IGA of disease severity of the intertriginous areas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With &quot;Success&quot; According to Total Sign Score of the Intertriginous Areas at Week 8 (Visit 6) in the Double-blind Phase</measure>
    <time_frame>At Week 8 (end of treatment for double-blind phase)</time_frame>
    <description>The severity of the subject's psoriasis vulgaris on the intertriginous areas was evaluated in terms of the three clinical signs: redness, thickness and scaliness. All the defined intertriginous areas were rated separately using the same scale as for the investigator's assessment of clinical signs (redness, thickness and scaliness) of the face.&#xD;
For each clinical sign, a single score, reflecting the average severity of all psoriatic lesions on the face was determined according to the scale below:&#xD;
Redness 0 = none&#xD;
= mild&#xD;
= moderate&#xD;
= severe&#xD;
= very severe&#xD;
Thickness 0 = none&#xD;
= mild&#xD;
= moderate&#xD;
= severe&#xD;
= very severe&#xD;
Scaliness 0 = none&#xD;
= mild&#xD;
= moderate&#xD;
= severe&#xD;
= very severe&#xD;
A mean score was calculated for each sign (redness, thickness and scaliness) based on scores of all the defined intertriginous areas with psoriasis at baseline and the sum of these mean scores constituted the TSS.&#xD;
&quot;Success&quot; was defined as a TSS score of 0 or 1.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1245</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO 80190</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcipotriol 25 mcg/g plus 10 mg/g hydrocortisone ointment (LEO 80190)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 80190 vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ointment Vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcipotriol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcipotriol 25 mcg/g in the ointment vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrocortisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydrocortisone 10 mg/g in the ointment vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriol plus hydrocortisone (LEO 80190)</intervention_name>
    <description>Once daily application</description>
    <arm_group_label>LEO 80190</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 80190 Vehicle</intervention_name>
    <arm_group_label>LEO 80190 vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <arm_group_label>Hydrocortisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriol</intervention_name>
    <arm_group_label>Calcipotriol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of psoriasis vulgaris involving the face&#xD;
&#xD;
          -  Clinical signs of psoriasis vulgaris on the trunk and/or the limbs, or earlier&#xD;
             diagnosed with psoriasis vulgaris on the trunk and/or the limbs&#xD;
&#xD;
          -  An extent of psoriatic involvement of the face of at least 10 cm2 (the sum of all&#xD;
             facial lesions)&#xD;
&#xD;
          -  Treatment areas (the face and the intertriginous areas) amenable to topical treatment&#xD;
             with a maximum of 100 g of ointment per week&#xD;
&#xD;
          -  Disease severity graded as mild, moderate, severe or very severe according to the&#xD;
             investigator's global assessment of disease severity of the face&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systemic treatments with all other therapies than biologicals, with a potential effect&#xD;
             on psoriasis vulgaris (e.g., corticosteroids, vitamin D analogues, retinoids,&#xD;
             immunosuppressants) within the 4-week period prior to randomisation&#xD;
&#xD;
          -  Systemic use of biological treatments, whether marketed or not, directed against or&#xD;
             with a potential effect on psoriasis vulgaris (e.g., alefacept, efalizumab,&#xD;
             etanercept, infliximab, adalimumab) within 3 months prior to randomisation&#xD;
&#xD;
          -  PUVA therapy or Grenz ray therapy within the 4-week period prior to randomisation&#xD;
&#xD;
          -  UVB therapy within the 2-week period prior to randomisation&#xD;
&#xD;
          -  Topical treatment of the face and the intertriginous areas within the 2-week period&#xD;
             prior to randomisation (use of emollients is allowed on treatment areas during this&#xD;
             2-week period, but not during the double-blind phase of the study)&#xD;
&#xD;
          -  Topical treatment with very potent WHO group IV corticosteroids within the 2-week&#xD;
             period prior to randomisation&#xD;
&#xD;
          -  Initiation of or expected changes in concomitant medication that may affect psoriasis&#xD;
             vulgaris (e.g., beta blockers, anti-malaria drugs, lithium and ACE inhibitors) during&#xD;
             the study&#xD;
&#xD;
          -  Current diagnosis of erythrodermic, exfoliative, guttate or pustular psoriasis&#xD;
&#xD;
          -  Patients with any of the following conditions present on the treatment area: viral&#xD;
             (e.g., herpes or varicella) lesions of the skin, fungal and bacterial skin infections,&#xD;
             parasitic infections, skin manifestations in relation to syphilis or tuberculosis,&#xD;
             rosacea, perioral dermatitis, acne vulgaris, atrophic skin, striae atrophicae,&#xD;
             fragility of skin veins, ichthyosis, acne rosacea, ulcers and wounds&#xD;
&#xD;
          -  Other inflammatory skin diseases (e.g., seborrhoiec dermatitis, contact dermatitis and&#xD;
             cutaneous mycosis) that may confound the evaluation of psorisis vulgaris on the face&#xD;
             or on the intertriginous areas&#xD;
&#xD;
          -  Planned exposure to sun, UVA or UVB that may affect the psoriasis vulgaris during the&#xD;
             study&#xD;
&#xD;
          -  Known or suspected severe renal insufficiency or severe hepatic disorders&#xD;
&#xD;
          -  Known or suspected disorders of calcium metabolism associated with hypercalcaemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Bieber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology and Allergy, University of Bonn</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Croatia - managed by CRO</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Macedonia - managed by CRO</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slovenia - managed by CRO</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology and Allergy, University of Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Czech Republic - managed by CRO</name>
      <address>
        <city>Warszawa</city>
        <zip>02-019</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hungary - managed by CRO</name>
      <address>
        <city>Warszawa</city>
        <zip>02-019</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Latvia - managed by CRO</name>
      <address>
        <city>Warszawa</city>
        <zip>02-019</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poland - managed by CRO</name>
      <address>
        <city>Warszawa</city>
        <zip>02-019</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belgium - managed by CRO</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Netherlands - managed by CRO</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Serbia - managed by CRO</name>
      <address>
        <city>New Belgrade</city>
        <zip>11070</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Serbia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 3, 2008</study_first_submitted>
  <study_first_submitted_qc>June 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2008</study_first_posted>
  <results_first_submitted>January 29, 2018</results_first_submitted>
  <results_first_submitted_qc>August 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 26, 2021</results_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 1245 subjects were enrolled (informed consent signed and CRF started). Five subjects left the study during washout (2 screening failures, 2 lost to follow-up and 1 unacceptable adverse event). One subject attended Visit 1 but was not randomized (voluntary withdrawal). Therefore, 1239 of the enrolled subjects were randomized in the study.</recruitment_details>
      <pre_assignment_details>The Randomized double-blind phase of the study lasted up to 8 weeks, and was followed by a 52-week Open-label period in which participants had the opportunity to receive Calcipotriol 25 mcg/g plus 10 mg/g Hydrocortisone ointment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LEO 80190</title>
          <description>Once daily application Calcipotriol 25 mcg/g plus 10 mg/g hydrocortisone ointment (LEO 80190)</description>
        </group>
        <group group_id="P2">
          <title>Calcipotriol</title>
          <description>Once daily application&#xD;
Calcipotriol 25 mcg/g in the ointment vehicle</description>
        </group>
        <group group_id="P3">
          <title>Hydrocortisone</title>
          <description>Once daily application&#xD;
Hydrocortisone 10 mg/g in the ointment vehicle</description>
        </group>
        <group group_id="P4">
          <title>LEO 80190 Vehicle</title>
          <description>Once daily application&#xD;
Ointment Vehicle</description>
        </group>
        <group group_id="P5">
          <title>Open-label Phase</title>
          <description>LEO 80190 ointment : calcipotriol 25 mcg/g plus 10 mg/g hydrocortisone ointment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>8-week, Double-blind, 4-arm</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="353"/>
                <participants group_id="P2" count="342"/>
                <participants group_id="P3" count="363"/>
                <participants group_id="P4" count="181"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="325"/>
                <participants group_id="P2" count="308"/>
                <participants group_id="P3" count="340"/>
                <participants group_id="P4" count="169"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>52-week, Open-label, Single Arm</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="454"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="403"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LEO 80190</title>
          <description>Once daily application Calcipotriol 25 mcg/g plus 10 mg/g hydrocortisone ointment (LEO 80190)</description>
        </group>
        <group group_id="B2">
          <title>Calcipotriol</title>
          <description>Once daily application Calcipotriol 25 mcg/g in the ointment vehicle</description>
        </group>
        <group group_id="B3">
          <title>Hydrocortisone</title>
          <description>Once daily application Hydrocortisone 10 mg/g in the ointment vehicle</description>
        </group>
        <group group_id="B4">
          <title>LEO 80190 Vehicle</title>
          <description>Once daily application Ointment Vehicle</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="353"/>
            <count group_id="B2" value="342"/>
            <count group_id="B3" value="363"/>
            <count group_id="B4" value="181"/>
            <count group_id="B5" value="1239"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.8" spread="15.3"/>
                    <measurement group_id="B2" value="44.8" spread="15.1"/>
                    <measurement group_id="B3" value="43.0" spread="14.1"/>
                    <measurement group_id="B4" value="44.6" spread="15.1"/>
                    <measurement group_id="B5" value="43.6" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="147"/>
                    <measurement group_id="B4" value="76"/>
                    <measurement group_id="B5" value="517"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="203"/>
                    <measurement group_id="B3" value="216"/>
                    <measurement group_id="B4" value="105"/>
                    <measurement group_id="B5" value="722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latvia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Macedonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With &quot;Controlled Disease&quot; According to the Investigator's Global Assessment(IGA) of Disease Severity of the Face at Week 8 (Visit 6) in the Double-blind Phase</title>
        <description>The (sub) investigator made an assessment of the disease severity of the face using the 6-category scale below.&#xD;
Clear, Almost clear, Mild, Moderate, Severe, Very severe&#xD;
The assessment was made considering the condition of psoriasis vulgaris of the face at the time of the evaluation, not in relation to the condition at a previous visit.&#xD;
For subjects with a baseline (Visit 1) severity of moderate or worse - &quot;controlled disease&quot; of the face was defined as clear or almost clear according to the IGA of disease severity of the face.&#xD;
For subjects with a baseline (Visit 1) severity of mild - &quot;controlled disease&quot; of the face was defined as clear according to the IGA of disease severity of the face.</description>
        <time_frame>At Week 8 (end of treatment for double-blind phase)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 80190</title>
            <description>Once daily application Calcipotriol plus hydrocortisone (LEO 80190)</description>
          </group>
          <group group_id="O2">
            <title>Calcipotriol</title>
            <description>Once daily application Calcipotriol 25 mcg/g in the ointment vehicle</description>
          </group>
          <group group_id="O3">
            <title>Hydrocortisone</title>
            <description>Once daily application Hydrocortisone 10 mg/g in the ointment vehicle</description>
          </group>
          <group group_id="O4">
            <title>LEO 80190 Vehicle</title>
            <description>Once daily application Ointment Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With &quot;Controlled Disease&quot; According to the Investigator's Global Assessment(IGA) of Disease Severity of the Face at Week 8 (Visit 6) in the Double-blind Phase</title>
          <description>The (sub) investigator made an assessment of the disease severity of the face using the 6-category scale below.&#xD;
Clear, Almost clear, Mild, Moderate, Severe, Very severe&#xD;
The assessment was made considering the condition of psoriasis vulgaris of the face at the time of the evaluation, not in relation to the condition at a previous visit.&#xD;
For subjects with a baseline (Visit 1) severity of moderate or worse - &quot;controlled disease&quot; of the face was defined as clear or almost clear according to the IGA of disease severity of the face.&#xD;
For subjects with a baseline (Visit 1) severity of mild - &quot;controlled disease&quot; of the face was defined as clear according to the IGA of disease severity of the face.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="353"/>
                <count group_id="O2" value="341"/>
                <count group_id="O3" value="363"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="135"/>
                    <measurement group_id="O3" value="115"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for superiority of LEO 80190 ointment versus calcipotriol ointment at Week 8 LOCF (Last Observation Carried Forward).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test for superiority of LEO 80190 ointment versus hydrocortisone ointment at Week 8 LOCF (Last Observation Carried Forward).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.31</ci_lower_limit>
            <ci_upper_limit>2.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Test for superiority of LEO 80190 ointment versus ointment vehicle at Week 8 LOCF (Last Observation Carried Forward).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.80</ci_lower_limit>
            <ci_upper_limit>4.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With &quot;Controlled Disease&quot; According to the IGA of Disease Severity of the Face at Week 4 (Visit 4) in the Double-blind Phase</title>
        <description>The assessment of the disease severity of the face was made using the 6-category scale below.&#xD;
Clear Almost clear Mild Moderate Severe Very severe&#xD;
The assessment was made considering the condition of psoriasis vulgaris of the face at the time of the evaluation, not in relation to the condition at a previous visit.&#xD;
For subjects with a baseline severity of moderate or worse - &quot;controlled disease&quot; of the face was defined as clear or almost clear according to the IGA of disease severity of the face.&#xD;
For subjects with a baseline severity of mild - &quot;controlled disease&quot; of the face was defined as clear according to the IGA of disease severity of the face.</description>
        <time_frame>At Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 80190</title>
            <description>Once daily application Calcipotriol plus hydrocortisone (LEO 80190)</description>
          </group>
          <group group_id="O2">
            <title>Calcipotriol</title>
            <description>Once daily application Calcipotriol 25 mcg/g in the ointment vehicle</description>
          </group>
          <group group_id="O3">
            <title>Hydrocortisone</title>
            <description>Once daily application Hydrocortisone 10 mg/g in the ointment vehicle</description>
          </group>
          <group group_id="O4">
            <title>LEO 80190 Vehicle</title>
            <description>Once daily application Ointment Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With &quot;Controlled Disease&quot; According to the IGA of Disease Severity of the Face at Week 4 (Visit 4) in the Double-blind Phase</title>
          <description>The assessment of the disease severity of the face was made using the 6-category scale below.&#xD;
Clear Almost clear Mild Moderate Severe Very severe&#xD;
The assessment was made considering the condition of psoriasis vulgaris of the face at the time of the evaluation, not in relation to the condition at a previous visit.&#xD;
For subjects with a baseline severity of moderate or worse - &quot;controlled disease&quot; of the face was defined as clear or almost clear according to the IGA of disease severity of the face.&#xD;
For subjects with a baseline severity of mild - &quot;controlled disease&quot; of the face was defined as clear according to the IGA of disease severity of the face.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="353"/>
                <count group_id="O2" value="341"/>
                <count group_id="O3" value="363"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With &quot;Success&quot; According to Total Sign Score (TSS) of the Face at Week 8 (Visit 6) in the Double-blind Phase</title>
        <description>&quot;Success&quot; was defined as a TSS score of 0 or 1.&#xD;
For each clinical sign, a single score, reflecting the average severity of all psoriatic lesions on the face was determined according to the scale below:&#xD;
Redness 0 = none (no erythema) 1 = mild (faint erythema, pink to very light red) 2 = moderate (definite light red erythema) 3 = severe (dark red erythema) 4 = very severe (very dark red erythema) Thickness 0 = none (no plaque elevation) 1 = mild (slight, barely perceptible elevation) 2 = moderate (definite elevation but not thick) 3 = severe (definite elevation, thick plaque with sharp edge) 4 = very severe (very thick plaque with sharp edge) Scaliness 0 = none (no scaling) 1 = mild (sparse, fine-scale lesions, only partially covered) 2 = moderate (coarser scales, most of lesions covered) 3 = severe (entire lesion covered with coarse scales) 4 = very severe (very thick coarse scales, possibly fissured)&#xD;
The sum of the three scores constituted a TSS ranging from 0 to 12</description>
        <time_frame>At Week 8 (end of treatment for double-blind phase)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 80190</title>
            <description>Once daily application Calcipotriol plus hydrocortisone (LEO 80190)</description>
          </group>
          <group group_id="O2">
            <title>Calcipotriol</title>
            <description>Once daily application Calcipotriol 25 mcg/g in the ointment vehicle</description>
          </group>
          <group group_id="O3">
            <title>Hydrocortisone</title>
            <description>Once daily application Hydrocortisone 10 mg/g in the ointment vehicle</description>
          </group>
          <group group_id="O4">
            <title>LEO 80190 Vehicle</title>
            <description>Once daily application Ointment Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With &quot;Success&quot; According to Total Sign Score (TSS) of the Face at Week 8 (Visit 6) in the Double-blind Phase</title>
          <description>&quot;Success&quot; was defined as a TSS score of 0 or 1.&#xD;
For each clinical sign, a single score, reflecting the average severity of all psoriatic lesions on the face was determined according to the scale below:&#xD;
Redness 0 = none (no erythema) 1 = mild (faint erythema, pink to very light red) 2 = moderate (definite light red erythema) 3 = severe (dark red erythema) 4 = very severe (very dark red erythema) Thickness 0 = none (no plaque elevation) 1 = mild (slight, barely perceptible elevation) 2 = moderate (definite elevation but not thick) 3 = severe (definite elevation, thick plaque with sharp edge) 4 = very severe (very thick plaque with sharp edge) Scaliness 0 = none (no scaling) 1 = mild (sparse, fine-scale lesions, only partially covered) 2 = moderate (coarser scales, most of lesions covered) 3 = severe (entire lesion covered with coarse scales) 4 = very severe (very thick coarse scales, possibly fissured)&#xD;
The sum of the three scores constituted a TSS ranging from 0 to 12</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="353"/>
                <count group_id="O2" value="341"/>
                <count group_id="O3" value="363"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="136"/>
                    <measurement group_id="O3" value="131"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With &quot;Controlled Disease&quot; According to the IGA of Disease Severity of the Intertriginous Areas at Week 8 (Visit 6) in the Double-blind Phase</title>
        <description>The (sub)investigator made an assessment of the disease severity of the intertriginous areas using the 6-category scale below.&#xD;
Clear, Almost clear, Mild, Moderate, Severe, Very severe The assessment was made considering the condition of psoriasis vulgaris of the intertrigi-nous areas at the time of the evaluation, not in relation to the condition at a previous visit.&#xD;
For subjects with a baseline severity of moderate or worse - &quot;controlled disease&quot; of the intertriginous areas was defined as clear or almost clear according to the IGA of disease severity of the intertriginous areas.&#xD;
For subjects with a baseline severity of mild - &quot;controlled disease&quot; of the intertriginous areas was defined as clear according to the IGA of disease severity of the intertriginous areas.</description>
        <time_frame>At Week 8 (end of treatment for double-blind phase)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 80190</title>
            <description>Once daily application Calcipotriol plus hydrocortisone (LEO 80190)</description>
          </group>
          <group group_id="O2">
            <title>Calcipotriol</title>
            <description>Once daily application Calcipotriol 25 mcg/g in the ointment vehicle</description>
          </group>
          <group group_id="O3">
            <title>Hydrocortisone</title>
            <description>Once daily application Hydrocortisone 10 mg/g in the ointment vehicle</description>
          </group>
          <group group_id="O4">
            <title>LEO 80190 Vehicle</title>
            <description>Once daily application Ointment Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With &quot;Controlled Disease&quot; According to the IGA of Disease Severity of the Intertriginous Areas at Week 8 (Visit 6) in the Double-blind Phase</title>
          <description>The (sub)investigator made an assessment of the disease severity of the intertriginous areas using the 6-category scale below.&#xD;
Clear, Almost clear, Mild, Moderate, Severe, Very severe The assessment was made considering the condition of psoriasis vulgaris of the intertrigi-nous areas at the time of the evaluation, not in relation to the condition at a previous visit.&#xD;
For subjects with a baseline severity of moderate or worse - &quot;controlled disease&quot; of the intertriginous areas was defined as clear or almost clear according to the IGA of disease severity of the intertriginous areas.&#xD;
For subjects with a baseline severity of mild - &quot;controlled disease&quot; of the intertriginous areas was defined as clear according to the IGA of disease severity of the intertriginous areas.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="182"/>
                <count group_id="O4" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With &quot;Success&quot; According to Total Sign Score of the Intertriginous Areas at Week 8 (Visit 6) in the Double-blind Phase</title>
        <description>The severity of the subject's psoriasis vulgaris on the intertriginous areas was evaluated in terms of the three clinical signs: redness, thickness and scaliness. All the defined intertriginous areas were rated separately using the same scale as for the investigator's assessment of clinical signs (redness, thickness and scaliness) of the face.&#xD;
For each clinical sign, a single score, reflecting the average severity of all psoriatic lesions on the face was determined according to the scale below:&#xD;
Redness 0 = none&#xD;
= mild&#xD;
= moderate&#xD;
= severe&#xD;
= very severe&#xD;
Thickness 0 = none&#xD;
= mild&#xD;
= moderate&#xD;
= severe&#xD;
= very severe&#xD;
Scaliness 0 = none&#xD;
= mild&#xD;
= moderate&#xD;
= severe&#xD;
= very severe&#xD;
A mean score was calculated for each sign (redness, thickness and scaliness) based on scores of all the defined intertriginous areas with psoriasis at baseline and the sum of these mean scores constituted the TSS.&#xD;
&quot;Success&quot; was defined as a TSS score of 0 or 1.</description>
        <time_frame>At Week 8 (end of treatment for double-blind phase)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 80190</title>
            <description>Once daily application Calcipotriol plus hydrocortisone (LEO 80190)</description>
          </group>
          <group group_id="O2">
            <title>Calcipotriol</title>
            <description>Once daily application Calcipotriol 25 mcg/g in the ointment vehicle</description>
          </group>
          <group group_id="O3">
            <title>Hydrocortisone</title>
            <description>Once daily application Hydrocortisone 10 mg/g in the ointment vehicle</description>
          </group>
          <group group_id="O4">
            <title>LEO 80190 Vehicle</title>
            <description>Once daily application Ointment Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With &quot;Success&quot; According to Total Sign Score of the Intertriginous Areas at Week 8 (Visit 6) in the Double-blind Phase</title>
          <description>The severity of the subject's psoriasis vulgaris on the intertriginous areas was evaluated in terms of the three clinical signs: redness, thickness and scaliness. All the defined intertriginous areas were rated separately using the same scale as for the investigator's assessment of clinical signs (redness, thickness and scaliness) of the face.&#xD;
For each clinical sign, a single score, reflecting the average severity of all psoriatic lesions on the face was determined according to the scale below:&#xD;
Redness 0 = none&#xD;
= mild&#xD;
= moderate&#xD;
= severe&#xD;
= very severe&#xD;
Thickness 0 = none&#xD;
= mild&#xD;
= moderate&#xD;
= severe&#xD;
= very severe&#xD;
Scaliness 0 = none&#xD;
= mild&#xD;
= moderate&#xD;
= severe&#xD;
= very severe&#xD;
A mean score was calculated for each sign (redness, thickness and scaliness) based on scores of all the defined intertriginous areas with psoriasis at baseline and the sum of these mean scores constituted the TSS.&#xD;
&quot;Success&quot; was defined as a TSS score of 0 or 1.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="182"/>
                <count group_id="O4" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Double-blind Phase: From baseline (Day 0) to end of trial (Day 562) + Follow-up (Day 142) Open-label Phase: From Week 8 to Week 60 7 days + Follow-up (Day 142)</time_frame>
      <desc>The adverse events where collected for the the safety analysis set (SAS). The SAS consisted of those randomized patients who received any treatment with trial medication and for whom the presence or confirmed absence of adverse events were available. In total, 1235 subjects are included in the safety analysis set.</desc>
      <group_list>
        <group group_id="E1">
          <title>LEO 80190</title>
          <description>Once daily application Calcipotriol plus hydrocortisone (LEO 80190)</description>
        </group>
        <group group_id="E2">
          <title>Calcipotriol</title>
          <description>Once daily application Calcipotriol 25 mcg/g in the ointment vehicle</description>
        </group>
        <group group_id="E3">
          <title>Hydrocortisone</title>
          <description>Once daily application Hydrocortisone 10 mg/g in the ointment vehicle</description>
        </group>
        <group group_id="E4">
          <title>LEO 80190 Vehicle</title>
          <description>Once daily application Ointment Vehicle</description>
        </group>
        <group group_id="E5">
          <title>Open-label Phase</title>
          <description>LEO 80190 ointment : calcipotriol 25 mcg/g plus 10 mg/g hydrocortisone ointment</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (6.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Deafness traumatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Cervical vertebra injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign bone neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Laryngeal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Panic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (6.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="266" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="55" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Cystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="114" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Company acknowledges the investigators' right to publish the entire results of the study, irrespective of outcome. The Company retains the right to have any publication submitted to the Company for review at least 30 days prior to the same paper being submit-ted for publication or presentation. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Manager</name_or_title>
      <organization>LEO Pharma A/S</organization>
      <phone>+45 4494 5888</phone>
      <email>disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

